A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell LymphomaMiguel‐Angel Perales, Cameron J. Turtle, Joseph P. McGuirk et al.|Blood|2022Cited by 1
Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic MalignanciesKrina K. Patel, Miguel‐Angel Perales, Nina Shah et al.|Blood|2022Cited by 0